Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy
Authors:
- 10 April 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (11) , 2574-2576
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II studyAnnals of Oncology, 2004
- Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803Journal of Clinical Oncology, 2004
- Treatment of metastatic esophagus and gastric cancer.Seminars in Oncology, 2004
- Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trialAnnals of Oncology, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- The Hypercoagulable State of Malignancy: Pathogenesis and Current DebateNeoplasia, 2002
- CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinomaCancer, 2002
- Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent PanelJournal of Clinical Oncology, 2001
- Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric CancerJournal of Clinical Oncology, 1999